Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

"The idea of giving up and going home is simply not in the cards," CEO Mills says.

You may also be interested in...

Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come

Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector

The rapidly evolving stem cell space may have matured to the level where a single company’s misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following Osiris Therapeutics’ recent announcement that its mesenchymal stem cell therapy Prochymal produced mixed results in an interim look at a study of 62 patients with chronic obstructive pulmonary disease.

Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD

Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts